Clinical translation of bioartificial liver support systems with human pluripotent stem cell-derived hepatic cells

Figure 3 A strategy and cell number estimate of human pluripotent stem cells-derived hepatic cells in the mass production of bioartificial liver devices. Undifferentiated human pluripotent stem cells (hPSCs) can be expanded in a 15 L suspension culture system up to a maximum of 15 billion cells[37]. Three of these suspension culture flasks will be required to prepare 45 billion cells for a clinical-scale bioartificial liver (BAL) device. After inducing hepatic differentiation, the hPSC-derived hepatic cells will be cultured at high density in bioreactors to generate a BAL device.